why choose us

First received: July 05, 2023

Clinical Trial: Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Study Status: Completed

Recruit Status: RECRUITING

Condition: Chronic Lymphocytic Leukemia

Study Type: INTERVENTIONAL


Official Title: A Phase Ib Study Evaluating the Safety and Efficacy of Tafasitamab, Acalabrutinib, and Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Brief Summary: This phase Ib trial tests the safety and effectiveness of tafasitamab, acalabrutinib, and obinutuzumab in treating patients with previously untreated chronic lymphocytic leukemia (CLL).CLL is a type of cancer that develops from a specific white blood cell called B cells or B lymphocytes.Tafasitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread.Acalabrutinib is in a class of medications called kinase inhibitors.It blocks a protein called BTK, which…

Read more